PMID: 7694298

Smit LS, Wilkinson DJ, Mansoura MK, Collins FS, Dawson DC
Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator.
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9963-7., [PubMed]
Sentences
No. Mutations Sentence Comment
39 ABCC7 p.Val1475Met
X
ABCC7 p.Val1475Met 7694298:39:94
status: NEW
view ABCC7 p.Val1475Met details
The full-length constructs contained a valine-for-methionine substitution at amino acid 1475 (V1475M). Login to comment
60 ABCC7 p.Asp1370Asn
X
ABCC7 p.Asp1370Asn 7694298:60:106
status: NEW
view ABCC7 p.Asp1370Asn details
ABCC7 p.Gly551Ala
X
ABCC7 p.Gly551Ala 7694298:60:79
status: NEW
view ABCC7 p.Gly551Ala details
ABCC7 p.Lys1250Gln
X
ABCC7 p.Lys1250Gln 7694298:60:94
status: NEW
view ABCC7 p.Lys1250Gln details
ABCC7 p.Gly1349Ala
X
ABCC7 p.Gly1349Ala 7694298:60:86
status: NEW
view ABCC7 p.Gly1349Ala details
For this reason, expression levels for easily activated constructs (wild type, G551A, G1349A, K1250Q, and D1370N) were adjusted by reducing the amount of injected RNA so that the maximum Cl- conductance was similar to that attained by less sensitive constructs. Login to comment
66 ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:66:29
status: NEW
view ABCC7 p.Gly551Ser details
As previously reported (18), G551S, a mutation associated with mild disease (34), exhibited a moderate reduction in sensitivity (K1l2 = 1.1 mM IBMX) compared to wild-type (Kl2 = 0.3 mM). Login to comment
67 ABCC7 p.Gly1349Ser
X
ABCC7 p.Gly1349Ser 7694298:67:36
status: NEW
view ABCC7 p.Gly1349Ser details
The analogous substitution in NBF2 (G1349S), although not identified in patients, produced a virtually identical reduction in sensitivity (K1l2 = 1.1 mM IBMX). Login to comment
68 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 7694298:68:0
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:68:187
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 7694298:68:47
status: NEW
view ABCC7 p.Gly1349Asp details
ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 7694298:68:247
status: NEW
view ABCC7 p.Gly1349Asp details
ABCC7 p.Gly1349Ser
X
ABCC7 p.Gly1349Ser 7694298:68:232
status: NEW
view ABCC7 p.Gly1349Ser details
ABCC7 p.Gly551Ala
X
ABCC7 p.Gly551Ala 7694298:68:177
status: NEW
view ABCC7 p.Gly551Ala details
ABCC7 p.Gly1349Ala
X
ABCC7 p.Gly1349Ala 7694298:68:217
status: NEW
view ABCC7 p.Gly1349Ala details
G551D, associated with severe CF (35, 36), and G1349D, also a CF mutation (37), both exhibited a dramatic reduction in sensitivity (K1l2 = 2.5 0 0 wt (12) 100 E .E CO) NBF1 A A G551A c O G551S V v G551 D NBF2 (8) A-A G1349A (9) * * G1349S (6) '-V G1349D (4) (6) (8) 0.2 0.5 1 IBMX, mM FIG. 2. Login to comment
77 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 7694298:77:167
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:77:150
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 7694298:77:173
status: NEW
view ABCC7 p.Gly1349Asp details
ABCC7 p.Gly1349Ser
X
ABCC7 p.Gly1349Ser 7694298:77:156
status: NEW
view ABCC7 p.Gly1349Ser details
To explore further the relative contributions of the two domains, we measured the activation of Cl- currents in oocytes expressing the double mutants G551S/G1349S and G551D/G1349D. Login to comment
86 ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:86:153
status: NEW
view ABCC7 p.Gly551Ser details
In NBF1 the substitution resulted in a moderate reduction in the sensitivity of CFTR to activation (K1l2 = 0.8 mM), roughly equivalent to that seen with G551S. Login to comment
89 ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 7694298:89:185
status: NEW
view ABCC7 p.Lys1250Ala details
ABCC7 p.Lys464Ala
X
ABCC7 p.Lys464Ala 7694298:89:154
status: NEW
view ABCC7 p.Lys464Ala details
ABCC7 p.Lys1250Arg
X
ABCC7 p.Lys1250Arg 7694298:89:195
status: NEW
view ABCC7 p.Lys1250Arg details
ABCC7 p.Lys464Arg
X
ABCC7 p.Lys464Arg 7694298:89:12
status: NEW
view ABCC7 p.Lys464Arg details
ABCC7 p.Lys464Arg
X
ABCC7 p.Lys464Arg 7694298:89:163
status: NEW
view ABCC7 p.Lys464Arg details
Alanine and arginine substitutions at lysine-464 and -1250 were associated with sensitivities similar to those observed with the glutamine substitutions (K464A or K464R, Kil2 = 0.8 mM; K1250A or K1250R, K,12 < 0.02 mM). Login to comment
92 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 7694298:92:80
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:92:66
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:92:123
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly1349Ser
X
ABCC7 p.Gly1349Ser 7694298:92:131
status: NEW
view ABCC7 p.Gly1349Ser details
ABCC7 p.Lys464Gln
X
ABCC7 p.Lys464Gln 7694298:92:273
status: NEW
view ABCC7 p.Lys464Gln details
The dose- 100- g 80-E C3) ° 60- V ai) X 40- E co 20 NBF1 O O G551S (9) v-v G551D (6) 0 Owt (12) T 6o NBF1 + NBF2 O--O G551S + G1349S (7) *--* G551 D + G 1 349D (5) Oz0 6 0 / T/ * , * /1 ° T 0 r / / / 3 _ -- ........ 0.02 0.05 0.2 0.5 1 2 IBMX, mM O-O wt (12) V-V K464Q ( 4) 1OOT 9 80E 0I-) I00160- -0 . Login to comment
93 ABCC7 p.Lys1250Gln
X
ABCC7 p.Lys1250Gln 7694298:93:25
status: NEW
view ABCC7 p.Lys1250Gln details
a) 40 E (1'- 20- Y + F-V K1250Q ( 4) 0 T~ ~ ~~~ /,/ I I I I T/T /V10 T/ v ~~~I I~~~~~~~~~ V V O ° ~~~~~T/ Q .y 1 0.02 0.05 0.2 0.5 1 IBMX, mM 2 5 FIG. 4. Login to comment
99 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 7694298:99:143
status: NEW
view ABCC7 p.Gly551Asp details
In NBF1, this substitution resulted in a dramatic reduction in sensitivity (K1l2 = 2.5 mM), roughly equivalent to that seen with AF508 (18) or G551D, whereas in NBF2, the identical substitution produced an increase in sensitivity to forskolin and IBMX (Kql2 = 0.02 mM). Login to comment
104 ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 7694298:104:74
status: NEW
view ABCC7 p.Gly1349Asp details
Even in the case of a mutation that severely compromised activation, e.g. G1349D, current-voltage plots were indistinguishable from wild type. Login to comment
107 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 7694298:107:71
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:107:40
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 7694298:107:79
status: NEW
view ABCC7 p.Gly1349Asp details
ABCC7 p.Gly1349Ser
X
ABCC7 p.Gly1349Ser 7694298:107:48
status: NEW
view ABCC7 p.Gly1349Ser details
Both glycines were replaced by serines (G551S + G1349S) or aspartates (G551D + G1349D), and the dose-response relationships were constructed as in Fig. 2. Login to comment
108 ABCC7 p.Asp1370Asn
X
ABCC7 p.Asp1370Asn 7694298:108:72
status: NEW
view ABCC7 p.Asp1370Asn details
A 80+ 60 + 40+- 20 + wt rl% - 7 1 k (12) t rd:\z-Za uab/ZN k b) A-- K A D1370N ( 5) T/ z T A T I I 0 f I~0A I~~~~~~ T t u A~~~~ 0.2. ,0.02 0.05 0.2 0.5 IBMX, mM 2 45 FIG. 5. Login to comment
119 ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 7694298:119:114
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 7694298:119:123
status: NEW
view ABCC7 p.Gly1349Asp details
Anderson and Welsh (28) found that in detached patches from transfected cells, mutation of the conserved glycine (G551S or G1349D) dramatically reduced the value ofthe open probability (PO) in the presence ofPKA and MgATP. Login to comment
129 ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 7694298:129:107
status: NEW
view ABCC7 p.Lys1250Met details
Of particular interest is the observation (28) that mutation of the Walker A lysine in NBF2 to methionine (K1250M) produced a 4-fold reduction in the apparent Kil2 for the activation of CFTR by ATP but also completely eliminated inhibition by 1 mM ADP. Login to comment